Table 1 Demographic characteristics for invasive breast cancer cases by each of the four investigated categories^a

Median (± SD) age at diagnosis (years)

57.3 ± 14.4

64.3 ± 16.3

61.9 ± 14.9

60.2 ± 13.8

60.2 ± 13.9

Race

   Caucasian

1,252 (62%)

783 (62%)

2,009 (66%)

52,280 (71%)

56,324 (70%)

   African-American

192 (10%)

126 (10%)

287 (9%)

4,008 (5%)

4,613 (6%)

   Hispanic

412 (20%)

220 (17%)

503 (16%)

10,188 (14%)

11,323 (14%)

   Asian

140 (7%)

122 (10%)

241 (8%)

6,808 (9%)

7,311 (9%)

   Other

18 (0.9%)

17 (1%)

19 (0.6%)

474 (0.6%)

528 (0.7%)

Stage

   I

-

-

-

38,571 (52%)

38,571 (48%)

   IIA

-

-

-

21,308 (29%)

21,308 (27%)

   IIB

-

-

-

11,137 (15%)

11,137 (14%)

   IIIA

-

-

-

2,675 (4%)

2,675 (3%)

   IIIB

1,520 (75%)

1,268 (100%)

-

67 (<0.1%)

2,855 (4%)

   IV

494 (25%)

0 (0%)

3,059 (100%)

0 (0%)

3,553 (4%)

Tumor grade

   Grade 1

51 (3%)

82 (6%)

141 (5%)

16,458 (22%)

16,732 (21%)

   Grade 2

433 (22%)

363 (29%)

764 (25%)

28,873 (39%)

30,433 (38%)

   Grade 3

1,025 (51%)

616 (49%)

1,108 (36%)

21,466 (29%)

24,215 (38%)

   Grade 4

95 (5%)

38 (3%)

81 (3%)

1,536 (2%)

1,750 (2%)

   Unknown

410 (20%)

169 (13%)

965 (32%)

5,425 (7%)

6,969 (9%)

Estrogen receptor

   Estrogen receptor-positive

862 (56%)

653 (67%)

1,533 (73%)

49,960 (80%)

53,008 (79%)

   Estrogen receptor-negative

675 (44%)

319 (33%)

573 (27%)

12,419 (20%)

13,986 (21%)

   Missing

477

296

953

11,379

13,105

   Progesterone receptor

   Progesterone receptor-positive

666 (45%)

511 (54%)

1,123 (58%)

40,555 (68%)

42,855 (67%)

   Progesterone receptor-negative

819 (55%)

430 (46%)

826 (42%)

19,137 (32%)

21,212 (33%)

   Missing

529

327

1,110

14,066

16,032

Hormone receptor^b

   Hormone receptor-positive

916 (60%)

671 (69%)

1,578 (75%)

51,062 (82%)

54,227 (81%)

   Hormone receptor-negative

626 (40%)

303 (31%)

533 (25%)

11,499 (18%)

12,961 (19%)

   Missing

472

294

948

11,197

12,911

HER2

   HER2-positive

477 (40%)

255 (35%)

506 (35%)

9,575 (22%)

10,813 (23%)

   HER2-negative

703 (60%)

484 (65%)

942 (65%)

34,754 (78%)

36,883 (77%)

   Missing

834

529

1,611

29,429

32,403

Surgical treatment

   None

511 (25%)

218 (17%)

1,707 (56%)

612 (<1%)

3,048 (4%)

Mastectomy/lumpectomy/other

1,500 (75%)

1,050 (83%)

1,352 (44%)

73,145 (99%)

77,047 (96%)

   Unknown

3 (0.2%)

0 (0%)

0 (0%)

1 (0%)

4 (0%)

Radiation therapy

   None

1,022 (51%)

779 (61%)

2,041 (67%)

37,334 (51%)

41,176 (51%)

   Any

992 (49%)

489 (39%)

1,018 (33%)

36,422 (49%)

38,921 (49%)

   Unknown

0 (0%)

0 (0%)

0 (0%)

2 (0%)

2 (0%)

Chemotherapy

   None

351 (17%)

537 (42%)

1,345 (44%)

44,474 (60%)

46,707 (58%)

   Any

1,625 (81%)

683 (54%)

1,606 (53%)

27,428 (37%)

31,342 (39%)

   Unknown

38 (2%)

48 (4%)

108 (4%)

1,856 (3%)

2,050 (3%)

Socioeconomic status

   Lowest

358 (18%)

235 (19%)

509 (17%)

7,786 (11%)

8,888 (11%)

   Second lowest

379 (19%)

263 (21%)

584 (19%)

11,900 (16%)

13,126 (16%)

   Middle

427 (21%)

265 (21%)

631 (21%)

15,376 (21%)

16,699 (21%)

   High

465 (23%)

252 (20%)

705 (23%)

17,608 (24%)

19,030 (24%)

   Highest

385 (19%)

253 (20%)

630 (21%)

21,088 (29%)

22,356 (28%)